ReviewBiochimica et biophysica acta2012
Challenges in the clinical utility of the serum test for HER2 ECD.
Review in Biochimica et biophysica acta, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 76 citations in OpenAlex.
- Diagnostic value of serum HER2 levels in breast cancer: a systematic review and meta-analysis.BMC cancer · 2020Pooled it
- Five-weekly S-1 plus cisplatin therapy combined with trastuzumab therapy in HER2-positive gastric cancer: a phase II trial and biomarker study (WJOG7212G).Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2018Trial
- Differentiating borderline HER2-expressing and HER2-positive cancers from other subtypes using serum urokinase plasminogen activator.British journal of cancer · 2026Article
- Soluble isoforms of EGFR family in breast cancer: Advances and clinical relevance (Review).Oncology letters · 2026Review
- Clinical significance of CD166 and HER-2 in different types of gastric cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Article
- The unique monoclonal antibodies and immunochemical assay for comprehensive determination of the cell-bound and soluble HER2 in different biological samples.Scientific reports · 2024Article
- Serum HER2 Level Predicts Therapeutic Efficacy and Prognosis in Advanced Breast Cancer Patients.Breast cancer (Dove Medical Press) · 2024Article
- DNA-Directed Protein Anchoring on Oligo/Alkanethiol-Coated Gold Nanoparticles: A Versatile Platform for Biosensing Applications.Nanomaterials (Basel, Switzerland) · 2022Article
- Analysis of plasma HER2 copy number in cell-free DNA of breast cancer patients: a comparison with HER2 extracellular domain protein level in serum.Breast cancer (Tokyo, Japan) · 2021Article
- Challenges in Detection of Serum Oncoprotein: Relevance to Breast Cancer Diagnostics.Breast cancer (Dove Medical Press) · 2021Review
- Article
- Article
- Monitoring Value of Serum HER2 as a Predictive Biomarker in Patients with Metastatic Breast Cancer.Cancer management and research · 2020Article
- The extracellular domain of Her2 in serum as a biomarker of breast cancer.Laboratory investigation; a journal of technical methods and pathology · 2018Review
- Article
- Quantification of Circulating Cancer Biomarkers via Sensitive Topographic Measurements on Single Binder Nanoarrays.ACS omega · 2017Article
- Serum HER2 as a predictive biomarker for tissue HER2 status and prognosis in patients with gastric cancer.World journal of gastroenterology · 2017Article
- ERBB3: A potential serum biomarker for early detection and therapeutic target for devil facial tumour 1 (DFT1).PloS one · 2017Article
- A prospective study to assess the clinical utility of serum HER2 extracellular domain in breast cancer with HER2 overexpression.Breast cancer research and treatment · 2016Article
- Reply to the letter by Takeshi Yamada et al. concerning "Is serum HER2 ECD a predictive biomarker for response to trastuzumab in advanced gastric cancer?".Journal of gastroenterology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Approximately 15-30% of breast cancers over-express the HER2/neu receptor. Historically, over-expression of HER2/neu has been identified using IHC or FISH, both of which are invasive approaches requiring tissue samples. Recent evidence has shown that some tumors identified as "negative" using these methods can respond to HER2/neu targeted therapy. Shedding of the extracellular domain (ECD) of the receptor into the circulation has led to the development of a serum test of HER2 ECD as an additional approach to probe HER2/neu overexpression. The serum test will be able to monitor the dynamic changes of HER2 status over the course of disease progression. Some studies further suggest that the serum HER2 ECD level and its change may serve as a biomarker to reflect patients' response to therapy. Yet more than 10years after the first serum HER2 ECD test was approved by the FDA, serum HER2 testing has yet to be widely used in clinical practice. In this article we will review the progress of the serum HER2 ECD test and discuss some obstacles impeding its incorporation into broad clinical practice. We will also discuss recent improvements in the sensitivity and specificity of the assay that offer some hope for the future of serum HER2 test.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.